As UK biotech gains steam, Syncona launches new Treg player while Cambridge spinout expands Series A
Since merging with the public investment firm BACIT two-plus years ago, Syncona has made steady headway in the cell and gene therapy space: It …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
